Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
Date:5/5/2009

mated 49,960 deaths (American Cancer Society, Cancer Facts and Figures 2009). The current standard of care is associated with significant side effects including neuropathy, which can limit its use and result in its discontinuation. Effective first-line, neuropathy sparing treatment for CRC is a major unmet medical need.

About Prostate Cancer

More than 1 million American men are currently living with prostate cancer and it is the second leading cause of death among men in the U.S. In 2008, an estimated 186,320 new cases of prostate cancer were expected to be diagnosed in the U.S., with an estimated 28,660 deaths (American Cancer Society, Cancer Facts and Figures 2009). CRPC is prostate cancer that continues to grow despite current standard of care hormonal (anti-androgen) therapies. CRPC is more invasive and more likely to spread to other organs than androgen dependent prostate cancers. Patients with CRPC have few treatment options and a poor prognosis.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that it has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors. It is being studied in multiple cancer indications, treatment combinations and by two routes of administration.

Conference Call Details

Poniard's management team will host a live conference call and Webcast today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. To participate by telephone, please di
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)...  Boston Scientific has released the primary endpoint ... Failure (NECTAR-HF) clinical trial, the first and only ... (VNS) for the treatment of heart failure patients.  ... Cardiology and Director of the Clinical Investigation Center ... de la Recherche Medicale presented the results at ...
(Date:8/30/2014)... 30, 2014   Royal Philips  (NYSE: PHG, AEX: ... a new ultrasound system designed to enable global hospitals ... patient volumes and cost pressures. Making its debut at ... Barcelona this week, Affiniti provides ... with fewer resources deliver high quality patient care. ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... The report firstly reviews the basic information of ... manufacturing technology. The report then explores global and ... their product specification, capacity, Production value, and market ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
(Date:8/30/2014)... 30, 2014 According to Bloomberg ... that requires Takeda Pharmaceutical Co. and Eli Lilly & ... claims that the drugmakers concealed information about a risk ... The case, Allen v. Takeda Pharmaceuticals North America Inc. ... District of Louisiana (Lafayette).* , According to Bloomberg, Takeda ...
(Date:8/30/2014)... Recently, Skmen.com, a well-known clothing manufacturer, has ... . Before the middle of September, all the company’s ... from 15 to 30 percent off. , As ... outfits are carefully made and come with quality guarantees. ... wearers. Skmen.com is popular for its fashionable, high quality ...
(Date:8/30/2014)... CA (PRWEB) August 30, 2014 Ticket Down ... vs. Chile exhibition match next Saturday at Levi's Stadium. ... for diehard soccer fans in the United States due to the ... in just about every major city. Many of these games ... in Brazil this past summer. , Levi’s Stadium is a brand ...
(Date:8/30/2014)... 2014 Information supplied by insurance companies ... better prices to consumers in 2014. A group of ... when using the open system for adults at ... to use this year can help the average person ... location and not from medical histories. The finder tool ...
(Date:8/30/2014)... 2014 United Theological Seminary is pleased to ... the Master of Theological Studies (MTS). , ... designed for students who wish to pursue further academic study ... to serve the Church and community. Previously, students needed to ... can attend classes from any location where there is an ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Decision to Uphold $9 Billion Actos Award 2Health News:Huge Deals On 2014 Long Casual Dresses Unveiled By Skmen.com 2Health News:Mexico vs. Chile Tickets at Levi's Stadium in Santa Clara, CA: TicketDown.com Offers Promo Code for Mexico vs. Chile Exhibition Game on September 6th 2Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2Health News:United Theological Seminary Announces First Fully Online Degree 2
... finds increased risk of heart failure , , MONDAY, Dec. 22 (HealthDay ... inactivity increased the risk of heart failure in a major study ... overweight men who are not obese have an increase in heart ... on the finding in the Dec. 23 issue of Circulation ...
... December 22, 2008 The Women,s Heart Health Initiative ... creation of a new fellowship dedicated to gender-specific research ... heart disease in women. The announcement will take place ... , "Women face unique challenges to successful diagnosis ...
... almost 4 times the odds, study says , , MONDAY, ... increases a pregnant woman,s likelihood of having a Caesarean ... Boston University School of Medicine and Boston Medical Center ... pregnant women and Caesarean section. Of the 253 women ...
... of suffering from overweight and obesity. This is the result ... starting school. Elisabeth Weber and her coauthors present the results ... ( Dtsch Arztbl Int 2008; 105 [51-52]: 883-9). The ... of the children, but also their mother tongue. Their parents ...
... switch ,on, in those with lupus, rheumatoid arthritis , , ... potential autoimmune disease-causing cells, but these cells stay in ... cells that attack the body cause autoimmune diseases such ... cells in healthy adults are true precursors of the ...
... the Support of Long Term Care elects healthcare software expert Eric Christ ... ... -- The National Association for the Support of Long Term Care (NASL) ... the president of Patient Placement Systems , part of the Jackson ...
Cached Medicine News:Health News:Even a Little Overweight, Inactivity Hurts the Heart 2Health News:Eric Christ of Long-Term Care Software Leader Patient Placement Systems' Elected to NASL Board of Directors 2
... The Minifold I system consists of four basic ... plenum, and metal clamping plate (see diagram). The ... for producing spots, dots, or slots (see below). ... purchased as an accessory plate in conjunction with ...
... The Minifold I system consists of four basic ... plenum, and metal clamping plate (see diagram). The ... for producing spots, dots, or slots (see below). ... purchased as an accessory plate in conjunction with ...
... Bio-Dot SF (slot format) microfiltration units provide ... nucleic acid in solution onto nitrocellulose or ... accommodated by using interchangeable templates to form ... format Bio-Dot SF apparatus. Each is available ...
... The Bio-Dot and Bio-Dot SF (slot ... for binding protein or nucleic acid in ... experimental protocols can be accommodated by using ... apparatus or 48-well slot format Bio-Dot SF ...
Medicine Products: